Tokyo, Japan – January 30, 2018 – JSR Corporation has been granted an exclusive license for intellectual property from Keio University for the treatment and diagnosis of inflammatory bowel disease (IBD). JSR then granted exclusive licenses of the key intellectual property to BiomX Ltd., a microbiome drug discovery company developing customized phage therapies, to develop and commercialize phage therapies based on the intellectual property.
Jan. 23, 2018 - Sunnyvale, CA - JSR Life Sciences, the life sciences-focused business unit of JSR Corporation, announced today that it has appointed Dr. Nalini Murdter as the President and Chief Executive Officer of MBL International (MBLI) effective immediately.
TOKYO – Dec. 20, 2017 – JSR Life Sciences (JLS) announced today that JSR Corporation has agreed to purchase Crown Bioscience International (TPEx: ticker 6554) at 12 Billion New Taiwan Dollar, a global drug discovery and development services company providing translational platforms to advanced oncology, inflammation, cardiovascular and metabolic disease research. This acquisition marks JSR’s largest life sciences-focused investment to date, extending the company’s portfolio to include industry-leading contract research and development capa
Tokyo – Nov. 21, 2017 – JSR Corporation announced today that it held the opening ceremony of the JSR-Keio University Medical and Chemical Innovation Center (JKiC) on October 28 at the Keio University Shinanomachi Campus.
JSR Life Sciences, the life-sciences focused division of JSR Corporation, will offer industry partners best-in-class CDMO services by complementing its commercial subsidiary KBI Biopharma with Selexis SA Technologies
Durham, NC - May 23, 2017 - JSR Life Sciences (JLS) today announced that KBI Biopharma (KBI), a subsidiary of JSR Corporation (JSR), is expanding its biopharmaceutical manufacturing capacity and capabilities at both its Durham, North Carolina and Boulder, Colorado facilities. KBI is investing approximately $30M on the two site expansion projects, which will greatly enhance the offerings at each site and are scheduled for completion later this year.
Tokyo, Japan - May 9, 2017 – JSR Life Sciences (JLS), the global life sciences focused division of JSR Corporation, today announced plans for expansion of its production capabilities of Amsphere™ A3 protein-A chromatography resin at JSR’s Belgium subsidiary, JSR Micro NV. This expansion will effectively increase its production capacity by 6 times and provide all-important redundancy in its manufacturing capability.
Sunnyvale, CA, ‐ September 29, 2016 ‐ JSR Life Sciences has signed a technology licensing and joint development agreement for the Chromassette® technology with SPF Technologies, LLC, a private Somerville, MA‐based company providing innovative solutions for biopharmaceutical manufacturing.
April 21, 2016 – Sunnyvale, CA – JSR Micro, Inc. announced today that it has expanded the JSR Life Sciences business division by becoming the majority shareholder of Boston area-based MBL International Corporation (MBLI). Tim Lowery, Sr. Vice President of Emerging Technologies at JSR Micro, Inc., has been appointed as the Chief Executive Officer of MBLI effective immediately.
April 14, 2016 – Sunnyvale, CA – JSR Life Sciences Division (JLS) today announced the formation and establishment of its global corporate headquarters in Sunnyvale, CA USA. Eric R. Johnson will assume responsibility of all operations as Senior Executive Officer and General Manager Life Sciences Division. JLS US headquarters will be responsible for all commercial business activities including strategic planning, customer support, marketing and product development oversight.